ClinicalTrials.gg
TerminatedNCT06025110STRIDEUpdated Aug 14, 2025

A Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients

A Phase 2 interventional study of TCD601 and Placebo in Diabetes Mellitus, Type 1, sponsored by ITB-Med LLC. Terminated at 26 sites in 5 countries. Open to participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-08-14.

Sponsored by ITB-Med LLC · Phase 2, Interventional, and Treatment

Why this study was terminated
The study has been early terminated due to business reasons. This decision is not related to any safety, efficacy, or regulatory concerns.

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jan 2023, registered Aug 2023).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom — 32 open to participants now, 42 under way, 5 of them phase 3. Diabetes Mellitus, Type 1 · United Kingdom.

Enrollment
194th of 214
9 · median 50
Started
2023
with 16 others
Phase 2
25 of 268
3 open now
Registered
240th of 268
by date

Among the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, this one is the 194th largest by enrollment of the 214 interventional ones that give a count, is one of 17 that started in 2023, is one of 25 in phase 2, and was the 240th registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

32 of the 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom are open now. Recruiting first, the newest first:

27 more — sign in →

All 32 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 268 studies in Diabetes Mellitus, Type 1 with a site in United Kingdom, or all of them as a file.
02

Study summary

The goal of this study is to determine if treatment with TCD601 improves beta-cell function in adults recently diagnosed with type 1 diabetes compared to placebo.

03

Conditions studied

  • Diabetes Mellitus, Type 1
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand the study requirements and provide written before any study assessment is performed
  • Male or female patients ≥ 18 to 45 years of age
  • A diagnosis of type 1 diabetes

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant, lactating, or planning on pregnancy during the study
  • History of cancer
  • History of heart disease
  • Recent infection
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Participant)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    TCD601

    Administered one of three doses of TCD601 over a 12 week treatment period.

    Biological: TCD601

  • Placebo comparator
    Placebo

    Placebo is administered over a 12 week treatment period.

    Other: Placebo

Interventions

  • BiologicalTCD601

    Investigational Product

  • OtherPlacebo

    Comparator

06

What researchers measure

Primary outcomes

  1. Change from baseline in beta-cell function as compared to placebo at week 52.

    Assess any changes in beta-cell function at the end of the study (week 52) for patients treated with TCD601 (study drug) compared to subjects treated with placebo (the comparator).

    Time frame: 52 weeks

Secondary outcomes

  1. Assess the incidence and severity of adverse

    Number of adverse events compared to placebo at week 52.

    Time frame: 52 weeks

07

Study locations

26 sites
  • UZ Brussel
    Brussels, 1090, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Azienda Ospedaliero-Universitaria Renato Dulbecco
    Catanzaro, 88100, Italy
  • San Raffaele Hospital
    Milan, 20132, Italy
  • Luigi Sacco Hospital
    Milan, 20157, Italy
  • University of Siena
    Siena, 53100, Italy
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
  • Hospital Universitari de Girona Dr. Josep Trueta
    Girona, 17007, Spain
  • Hospital General de Segovia
    Segovia, 40002, Spain
  • Hospital Universitario Virgen del Rocío
    Seville, 41013, Spain
  • Hospital Clinico Universitario de Valladolid
    Valladolid, 47003, Spain
  • Karolinska University Hosptial
    Stockholm, Sweden
  • Dorset County Hospital NHS Foundation Trust
    Dorchester, Dorset DT1 2JY, United Kingdom
  • Liverpool University Hospitals NHS Foundation Trust
    Liverpool, Merseyside L7 8YE, United Kingdom
  • University of Birmingham
    Birmingham, United Kingdom
  • Bradford Teaching Hospitals NHS Foundation Trust
    Bradford, BD9 6DA, United Kingdom
  • Cambridge University Hospitals NHS Foundation Trust
    Cambridge, United Kingdom
  • Ninewells Hospital
    Dundee, DD1 9SY, United Kingdom
  • St George's University Hospitals NHS Foundation Trust
    London, SW17 0QT, United Kingdom
  • Guy's and St. Thomas' NHS Foundation Trust
    London, United Kingdom
  • East Kent Hospitals University NHS Foundation Trust
    Margate, CT9 4AN, United Kingdom
  • Norfolk and Norwich University Hospitals NHS Foundation Trust
    Norwich, NR4 7UY, United Kingdom
  • Oxford University Hospitals NHS Foundation Trust
    Oxford, OX3 7LE, United Kingdom
  • Northern Care Alliance NHS Foundation Trust
    Salford, M6 8HD, United Kingdom
  • Swansea Bay University Health Board
    Swansea, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Jul 2025, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2023
First posted
Sep 6, 2023
StartActual
Jan 23, 2023
Primary completionActual
Jul 24, 2025
CompletionActual
Jul 24, 2025
Last update
Aug 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06025110
Lead sponsor
ITB-Med LLC
Responsible party
Sponsor
First posted
Sep 6, 2023
Start date
Jan 23, 2023
Primary completion
Jul 24, 2025
Completion
Jul 24, 2025
Last update
Aug 14, 2025

Study contacts

Fredrik Juhlin
study director · ITB-MED

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Siplizumab

Start the discussion